ReviewCurrent osteoporosis reports2025
Pathophysiology of Bone Fragility in Type 2 Diabetes Mellitus.
Review in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessing bone microstructure and density with photon-counting CT: emerging applications and challenges.Skeletal radiology · 2026Review
- From the energy factory to the intercellular communication medium: the emerging role of intercellular mitochondrial transfer and mitochondrial transplantation therapy in diabetes and diabetic complications.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewIndividuals with type 2 diabetes mellitus (T2DM) are at greater risk of fragility fractures compared to those without diabetes despite comparable or higher bone mineral density (BMD). T2DM may increase skeletal fragility by altering aspects of bone quality including bone geometry, microstructure, tissue properties and remodeling independently of BMD, a parameter of bone quantity. The objective of this review is to synthesize recent work involving aspects of bone quantity and quality that may contribute to fragility in T2DM. RECENT
findingsCompared to those without diabetes, women with T2DM have less structurally robust hip geometries despite greater BMD after covariate adjustment. A growing body of evidence indicates that cancellous microarchitecture may be maintained in T2DM; however, cortical bone microarchitecture may be impacted by dysglycemia. Bone material properties - inclusive of tissue and/or compositional properties - and mechanical properties are influenced by T2DM. These include greater concentrations of advanced glycation end-products (AGEs) and increased tissue mineral content, changes associated with greater modulus and hardness, as well as reduced ductility and ability to mitigate damage accumulation. T2DM bone and serum markers indicate reduced bone remodeling compared to controls. Recent work bolsters prior observations reporting greater AGE and tissue mineral content in T2DM bone and reinforces findings of reduced remodeling. While some evidence indicates that these differences may adversely affect mechanical properties and result in stiffer, stronger - but more brittle - bone, this finding is not universal. Future studies require consideration of the multifactorial underpinnings of bone fragility in T2DM to guide screening, prevention strategies and fracture treatment in this at-risk population.
Indexed as
Identifiers
41026306What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.